QUICK Corp.

Equity Bottom-Up

<div>
The impact of COVID-19 raised awareness of prevention, and the Infection Control Business grew and performed well
<ul>
<li>
In 1H, sales and profits increased significantly The consolidated results for 1H of FY12/20 were sales of JPY11bn (2.3x YoY) and OP of JPY4.2bn (4.3x YoY), compared with the adjusted 1H of the previous term (non-audited company-published figures considering changes in the accounting period). Infection Control Business grew, resulting in a significant increase in sales and profits…</li>
</ul>
</div>

Notes: This is translated from our Japanese report issued on 21 Aug 2020.
Business performance was strong, as the infection control business grew due to the impact of COVID-19, and the full-year plan was revised
<ul>
<li>
In 1Q, sales and profits increased significantly The consolidated financial results for 1Q FY12/20 were sales of JPY5.8bn, 3.4x higher than the adjusted 1Q (unaudited company-published figures considering changes in accounting period) in FY12/19 (the same applies hereinafter) and OP of…</li>
</ul>

Japan

Taiko Pharmaceutical Co Ltd is a pharmaceutical company that manufactures and sells gastrointestinal pharmaceuticals and general use pharmaceutical products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00